Young adolescents across the globe could soon benefit from a simpler cancer prevention strategy, as health authorities reconsider whether a single dose of the HPV vaccine offers sufficient protection against a virus linked to thousands of cancer cases. With immunisation guidance in flux following political interference in the United States, both medical organisations and federal agencies are evaluating a potential “significant shift” in how adolescents are protected against human papillomavirus.
“This would be a significant shift in terms of what has been communicated for many years about the best way to protect adolescents against HPV,” said Jason Schwartz, a vaccine policy researcher at Yale University.
The potential change comes at a turbulent time for immunisation policy. In the United States, the childhood vaccination schedule has been subjected to political interference, with Health Secretary Robert F. Kennedy Jr. — a long-time vaccine sceptic — ordering in January that the recommended HPV dose be reduced to one. While that directive was blocked by a federal judge, the idea itself has been gaining traction among scientists.
Here is an examination of where the HPV vaccine stands after 20 years — and why the dosing debate matters.
The Cancer Link
Human papillomavirus is the most common sexually transmitted infection in the United States, with more than 40 types capable of infecting the genital areas as well as the lining of the mouth and throat. Certain strains are responsible for most cases of genital warts, but their most dangerous consequence is cancer.
HPV is a leading cause of nearly 50,000 cancer cases diagnosed annually in the US that affect those parts of the body. According to the Centers for Disease Control and Prevention, about 90 per cent of cervical cancer and anal cancer cases are attributed to HPV infections.
The first HPV vaccine, Merck & Co.’s Gardasil, was approved by federal health officials in 2006. A second vaccine, Glaxo
